These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36828738)

  • 1. Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering.
    Si K; Dai Z; Li Z; Ye Z; Ding B; Feng S; Sun B; Shen Y; Xiao Z
    Cytotherapy; 2023 Jun; 25(6):615-624. PubMed ID: 36828738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.
    Kamiya T; Wong D; Png YT; Campana D
    Blood Adv; 2018 Mar; 2(5):517-528. PubMed ID: 29507075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
    Billingsley MM; Singh N; Ravikumar P; Zhang R; June CH; Mitchell MJ
    Nano Lett; 2020 Mar; 20(3):1578-1589. PubMed ID: 31951421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
    Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
    Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.
    Stoiber S; Cadilha BL; Benmebarek MR; Lesch S; Endres S; Kobold S
    Cells; 2019 May; 8(5):. PubMed ID: 31108883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 12. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
    Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
    Front Immunol; 2022; 13():836549. PubMed ID: 35222427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoinjection: A Platform for Innovation in Ex Vivo Cell Engineering.
    Chen Y; Shokouhi AR; Voelcker NH; Elnathan R
    Acc Chem Res; 2024 Jun; 57(12):1722-1735. PubMed ID: 38819691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplified process for the production of anti-CD19-CAR-engineered T cells.
    Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
    Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy.
    Fan M; Liu H; Yan H; Che R; Jin Y; Yang X; Zhou X; Yang H; Ge K; Liang XJ; Zhang J; Li Z
    Biomaterials; 2022 Mar; 282():121424. PubMed ID: 35196606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo].
    Ren CX; Chen XX; Zhao L; Tian Y; Xu KL; Zhao K
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):506-512. PubMed ID: 35968595
    [No Abstract]   [Full Text] [Related]  

  • 18. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
    Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
    Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy.
    Metzloff AE; Padilla MS; Gong N; Billingsley MM; Han X; Merolle M; Mai D; Figueroa-Espada CG; Thatte AS; Haley RM; Mukalel AJ; Hamilton AG; Alameh MG; Weissman D; Sheppard NC; June CH; Mitchell MJ
    Adv Mater; 2024 Jun; 36(26):e2313226. PubMed ID: 38419362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.